ライフサイエンスコーパス: organ transplant

1 both murine and human recipients of a solid-organ transplant.

2 nts benefit from avoidance of morbidities of organ transplant.

3 ied to achieve these goals in the context of organ transplant.

4 d risk is higher among those who received an organ transplant.

5 re >/=2 years old and have not had HIV or an organ transplant.

6 d risk is higher among those who received an organ transplant.

7 transplant and patients who had received an organ transplant.

8 riority to help meet the clinical demand for organ transplant.

9 0.3%), liver transplant; and 6 (1.8%), mixed-organ transplant.

10 8 with a diagnosis of amyloidosis post solid-organ transplant.

11 on graft survival in several types of solid organ transplants.

12 thdrawal after cell therapy in recipients of organ transplants.

13 ng recipients of hematopoietic-cell or solid-organ transplants.

14 jor obstacle for long-term survival of solid organ transplants.

15 ic anemia and antibody-mediated rejection of organ transplants.

16 rials, such as foods, waterborne paints, and organ transplants.

17 il CMV infection and to purge the virus from organ transplants.

18 ical failure and rejection compared to other organ transplants.

19 ents, 17 lung, 13 liver, 9 heart, and 5 dual-organ transplants.

20 h cancer or recipients of stem cell or solid organ transplants.

21 ntation of hematopoietic stem cells or solid organ transplants.

22 Transplantation Network-a database of all US organ transplants.

23 ermined from small pediatric donors with >=1 organ transplanted.

24 21 deceased donors, resulting in 109 non-VCA organs transplanted (15 hearts, 3 intestine, 40 kidney,

25 tients, including HIV infection (45%), solid organ transplant (26%), and cirrhosis (22%).

26 first description of amyloidosis post solid-organ transplant; 30 cases among 5112 amyloid patients >

27 Organs from donors with ITP resulted in 49 organ transplants (31 kidney, 14 liver, four heart), wit

28 Created by the US National Organ Transplant Act in 1984, the Scientific Registry of

29 ecipients (SRTR) is mandated by the National Organ Transplant Act, the Final Rule, and the SRTR contr

30 Patients listed or being evaluated for solid organ transplant after January 26, 2018, were educated a

31 in immunocompromised individuals, including organ transplant and AIDS patients.

32 Thirty-five patients with a solid-organ transplant and chronic hepatitis E virus infection

33 rately for individuals who never received an organ transplant and patients who had received an organ

34 ce of EBV+ PTLD is variable depending on the organ transplanted and whether the recipient has preexis

35 ions for sensitized patients receiving solid organ transplants and antibody-mediated rejection treatm

36 small intestine by cell-turnover analysis in organ transplants and by retrospective cell birth dating

37 cells; it also underlies T cell rejection of organ transplants and drives graft-versus-host disease.

38 f C. difficile in hematology-oncology, solid organ transplant, and HIV-infected patients.

39 and numerous other solid organ malignancies, organ transplant, and immune suppression for nonmalignan

40 by donor/recipient CMV serostatus, year and organ transplanted, and clinical manifestation.

41 trials to treat patients with cancer, solid organ transplants, and autoimmune diseases.

42 immune diseases, allergies, atherosclerosis, organ transplants, and cancer.

43 splantation is among the lowest of all solid-organ transplants, and current diagnostic tests often fa

44 , including patients with neutropenia, solid organ transplants, and nonurologic surgery.

45 ver less prone to rejection than other solid organ transplants, and reaction to local injury, systemi

46 rction, stroke, hemorrhagic shock, and solid organ transplant are particularly prone to cause I-R inj

47 Organ transplants are rapidly rejected because T cells i

48 he goals of tolerance in patients with solid organ transplants are to eliminate the lifelong need for

49 ean [SEM] expression, 3.58 [1.50]; P = .15), organ transplant-associated cSCC (mean [SEM] expression,

50 We included pediatric recipients of solid organ transplants at the Hospital for Sick Children, Tor

51 This Banff Human Organ Transplant (B-HOT) panel is the culmination of pre

52 ment for immunosuppression compared to solid organ transplants because of the inherent immune privile

53 nors (aged <=8 y and weight <30 kg) with >=1 organ transplanted been used (as SpK when >10 kg) an add

54 mune responses and destruction of allogeneic organ transplants, but how this process is regulated on

55 of Transplant Recipients report cards of US organ transplant center performance are publicly availab

56 performed a cross-country survey of Canadian Organ Transplant centers to determine organ utilization

57 tory, in parallel with systems used by solid organ transplant centers.

58 Six organ transplanted children with GPTD were included in t

59 cipients that in turn has impacted the solid organ transplant community as well.

60 ti-HBc positivity in the absence of HBsAg in organ transplant donors and in candidate patients for ch

61 etrospective analysis of UNOS data for solid-organ transplant during a 25-year period (September 1, 1

62 ues to remain much higher than the number of organs transplanted each year.

63 rejection is the most common cause of solid organ transplant failure.

64 An increasing number of older people receive organ transplants for various end-stage conditions.

65 The charts of all patients receiving a solid organ transplant from 1990-2008 evaluated in the dermato

66 with end organ failure can safely receive an organ transplant from an HIV uninfected donor.

67 een in recipients receiving noncardiac solid organ transplants from simvastatin-treated donors.

68 d graft survival through 1 year of all solid organs transplanted from 370 donors who had been randoml

69 ne oxygenation and to analyze the outcome of organs transplanted from these donors.

70 In vascularized organ transplants, gender mismatches have higher rates o

71 Unwanted T cell responses during organ transplant, graft-versus-host disease, and allergi

72 l, recipients of hematopoietic-cell or solid-organ transplants (>=18 years of age, with CMV reactivat

73 nited States, an overall national decline in organ transplants has accompanied the substantial burden

74 Successful engraftment of organ transplants has traditionally relied on preventing

75 ation and avoidance protocols for post-solid organ transplant have been developed.

76 ers, bridges research in the fields of solid organ transplant, hematopoietic cell transplant, and org

77 entation such as cell regeneration, improved organ transplant, improved extracorporeal support and ar

78 ) in a cohort of US OTRs receiving a primary organ transplant in 2003 or 2008.

79 wever, most patients on the waiting list for organ transplant in the United States are nonwhite.

80 ibiting substantial growth in deceased donor organ transplants in Iran.

81 In transplantation, the survival of organs transplanted into obese patients is reduced compa

82 For HIV-positive individuals needing an organ transplant, issues of access, risk, and consent mu

83 event graft rejection in patients undergoing organ transplant it was also used to treat several syste

84 continuous distribution models for all solid organ transplants may allow for minimization of the geog

85 ed by the allocation priority given to multi-organ transplant (MOT) candidates.

86 Recipients of nonkidney solid organ transplants (nkSOT) are living longer, and 11%-18%

87 en-fold risk (25 to 30 fold risk after solid organ transplant) of colorectal cancer (CRC) than the ge

88 nts with cystic fibrosis who had received an organ transplant, optimal colonoscopy screening should s

89 ory of human immunodeficiency virus, cancer, organ transplants, or hereditary disease (albinism and x

90 Receiving a solid organ transplant owing to late-stage organ failure, foll

91 with a further 18% decrease in the number of organs transplanted (P = .0001).

92 Nocardia thailandica in a 66-year-old solid organ transplant patient from Connecticut, which was ide

93 Solid organ transplant patients with first episode of CMV dise

94 In the cohort of organ transplant patients with influenza A (n = 116), se

95 used to treat chronic HEV infection in solid-organ transplant patients with some success.

96 apenem-Resistant Enterobacteriaceae in Solid Organ Transplant Patients) has provided pivotal data on

97 In solid organ transplant patients, global suppression of innate

98 widely prescribed immunosuppressant drug for organ transplant patients, was directly quantified with

99 athogen that reactivates in immunosuppressed organ transplant patients.

100 d as a cause of persistent diarrhea in solid organ transplant patients.

101 d individuals, such as bone marrow and solid organ transplant patients.

102 cryptosporidiosis cases identified in solid organ transplanted patients between 2006 and 2010 in Fra

103 asting clinical disorder that may develop in organ-transplanted pediatric recipients.

104 ith a significant reduction in the number of organs transplanted per donor (incidence rate ratio 0.43

105 ciation between donor MDRO and (1) number of organs transplanted per donor and (2) the match run at w

106 ed with the standard risk donors (3.9 vs 4.2 organs transplanted per donor).

107 tioned to actual donation after BD, with 1.2 organs transplanted per donor.

108 e actual donors; range: 20.0-57.0%); and (2) organs transplanted per possible donor (range: 0.52-1.74

109 subsequent malignancy, however, the risk in organ transplant populations has not been evaluated.

110 potential donors) and organ transplant rate (organs transplanted/potential donors) must not fall sign

111 cancer of any type to determine the type of organ transplanted, pretransplant and posttransplant can

112 splantation lags behind that for other solid organ transplants, primarily because of allograft reject

113 (IRI) is an inevitable event in conventional organ transplant procedure and is associated with signif

114 Studying immune repertoire in the context of organ transplant provides important information on how a

115 rate (deceased donors/potential donors) and organ transplant rate (organs transplanted/potential don

116 andard, 36 (62%) failed to meet the proposed organ transplant rate standard, and 37 (64%) failed at l

117 for the donation rate and 5 for the proposed organ transplant rate standard.

118 l discuss key studies in the different solid organ transplants, recent reports of adverse events, and

119 ess of drug-drug interactions is critical in organ transplant recipient management.

120 ears were saved (observed to date) per solid-organ transplant recipient.

121 Hematopoietic-cell or solid-organ transplant recipients >=12 years old with RR CMV i

122 e medical record review of patients who were organ transplant recipients (154 were white and 259 nonw

123 We reported 47 solid organ transplant recipients (41 kidneys) with cryptospor

124 Of 495 high-risk organ transplant recipients (average age = 54 years, tim

125 isk factors of obesity among pediatric solid-organ transplant recipients (heart, lung, liver, kidney,

126 isk factors of obesity among pediatric solid-organ transplant recipients (heart, lung, liver, kidney,

127 Overall, 10649 organ transplant recipients (mean [SD] age, 51 [12] year

128 Solid-organ transplant recipients (OTRs) are at an increased r

129 Organ transplant recipients (OTRs) are at increased risk

130 Organ transplant recipients (OTRs) have a 100-fold incre

131 ll carcinoma (SCC) and other skin cancers in organ transplant recipients (OTRs), but evidence from mu

132 ed an increased risk of skin cancer in solid organ transplant recipients (OTRs), no study has estimat

133 s (cSCCs), particularly in immunocompromised organ transplant recipients (OTRs).

134 cancer has been well characterized in white organ transplant recipients (OTRs); however, most patien

135 De novo solid organ transplant recipients (SOTR) have a steep learning

136 Solid organ transplant recipients (SOTR) with a pretransplant

137 Solid organ transplant recipients (SOTr) with coronavirus dise

138 The number of solid organ transplant recipients (SOTR), and their life expec

139 accine effectiveness is not optimal in solid organ transplant recipients (SOTR).

140 significant opportunistic infection in solid organ transplant recipients (SOTR).

141 Immunosuppression (IS), such as in solid-organ transplant recipients (SOTRs) and patients with hu

142 Solid-organ transplant recipients (SOTRs) are at greater risk

143 h CMV DNA-positive plasma samples from solid-organ transplant recipients (SOTRs) were tested.

144 tributor to morbidity and mortality in solid organ transplant recipients (SOTRs).

145 s mellitus (PTDM) affects up to 50% of solid organ transplant recipients and compromises long-term ou

146 se in immunocompromised individuals, such as organ transplant recipients and infants infected in uter

147 disorder (PTLD) is a serious complication in organ transplant recipients and is most often associated

148 Diabetes is prevalent among solid organ transplant recipients and is universal among islet

149 advanced stage, which suggests that nonwhite organ transplant recipients are at even higher risk.

150 Organ transplant recipients are at high risk of developi

151 Solid organ transplant recipients are at increased risk for de

152 Solid-organ transplant recipients are at increased risk of dev

153 Conclusions and Relevance: Nonwhite organ transplant recipients are at risk for developing s

154 Solid organ transplant recipients are at risk for potentially

155 rials with expanded T(regs) in T1D and solid-organ transplant recipients are limited by poor T(reg) e

156 atment of chronic hepatitis C virus in solid organ transplant recipients are limited.

157 In conclusion, high-risk organ transplant recipients carry a substantial measurab

158 VZV immunization of pediatric solid organ transplant recipients confers sustained seroprotec

159 retrospective study that included 255 solid organ transplant recipients confirms that ribavirin is h

160 Pediatric solid organ transplant recipients demonstrate worse overall EF

161 ng novel immunotherapy combinations in solid organ transplant recipients designed to uncouple antitum

162 tion, a significant number of nonrenal solid organ transplant recipients develop chronic kidney disea

163 Risk factors for nonwhite organ transplant recipients differ between races/ethnici

164 Organ transplant recipients face life-long immunosuppres

165 Importance: Organ transplant recipients have a higher incidence of s

166 Solid organ transplant recipients have an increased risk of li

167 Solid organ transplant recipients have heightened risk for dif

168 Solid organ transplant recipients have increased risk for deve

169 to prevent nonmelanoma skin cancer in solid organ transplant recipients have not been summarized.

170 Elderly organ transplant recipients have remained underrepresent

171 We report four cases of COVID-19 in solid organ transplant recipients including recipients of kidn

172 s to support the postoperative care of solid organ transplant recipients is evolving.

173 Currently, 1 in 6 pediatric solid organ transplant recipients is hospitalized with a vacci

174 The increased skin cancer incidence in organ transplant recipients is well-known, but the skin

175 Solid organ transplant recipients may be at a high risk for SA

176 ocyte function-associated antigen (LFA)-1 in organ transplant recipients prolongs allograft survival.

177 stant Enterococcus faecium (LR-VRE) in solid organ transplant recipients remain uncommon, they repres

178 Still, the risk of SCC in organ transplant recipients remains much higher than in

179 and sun exposure/emigration history in Asian organ transplant recipients should be documented.

180 erobacteriaceae and CRE carriage among solid organ transplant recipients to inform management of this

181 Organ transplant recipients underwent full skin examinat

182 r was assessed among 118,440 Caucasian solid organ transplant recipients using multivariate Cox regre

183 The impact of these therapies in solid organ transplant recipients was not assessed in clinical

184 Organ transplant recipients were excluded.

185 Solid organ transplant recipients were identified within the N

186 ssociated with low PA in adult single, solid organ transplant recipients were included.

187 throughput gene expression datasets of solid organ transplant recipients were retrieved from the Gene

188 -center retrospective study of stem cell and organ transplant recipients who received letermovir for

189 Approximately 33.6% of nondiabetic solid organ transplant recipients who received tacrolimus deve

190 c of SARS-CoV-2, there is concern that solid organ transplant recipients will be particularly vulnera

191 Organ transplant recipients with CF should initiate CRC

192 In contrast, reports of solid organ transplant recipients with clinical features more

193 inical severity, and disease course in solid organ transplant recipients with COVID-19, including two

194 The proportion of examined organ transplant recipients with histopathologically con

195 ein report our initial experience with solid organ transplant recipients with SARS-CoV-2 infection at

196 Organ transplant recipients with the highest skin cancer

197 re recipient survival (as reported for other organ transplant recipients), graft survival, and uterus

198 NA was further detected in healthy skin of 4 organ transplant recipients, 2 of whom also had CuV-posi

199 The study cohort included 8026 organ transplant recipients, 5224 men (65.1%), with a me

200 lem in immunocompromised individuals such as organ transplant recipients, although the mechanism rema

201 tory of HPV infection, particularly in black organ transplant recipients, and sun exposure/emigration

202 o be safe and immunogenic in pediatric solid organ transplant recipients, but there are few data on t

203 d be part of posttransplantation care in all organ transplant recipients, including nonwhite patients

204 e susceptibility to CMV replication in solid-organ transplant recipients, particularly in patients no

205 noma skin cancer is well recognized in solid-organ transplant recipients, the risk of skin cancer in

206 o multiorgan recipients compared with single-organ transplant recipients, which raise ethical questio

207 se II trial, 152 treatment-naive adult solid organ transplant recipients, with CD20(+) PTLD unrespons

208 zed trials of eHealth interventions in solid organ transplant recipients.

209 r-seropositive/recipient-seronegative (D+R-) organ transplant recipients.

210 the hematology-oncology population and solid organ transplant recipients.

211 l cases occurring mostly in HIV patients and organ transplant recipients.

212 prevent nonmelanoma skin cancers among solid organ transplant recipients.

213 rcinoma (NPC), and lymphomas that develop in organ transplant recipients.

214 d adjunct immunosuppressive therapy in solid organ transplant recipients.

215 immunocompromised patients and particularly organ transplant recipients.

216 e incidence of rejection in HIV-to-HIV solid organ transplant recipients.

217 ases of antibody-mediated rejection in solid organ transplant recipients.

218 non-Hodgkin lymphoma (NHL) in 288 029 solid organ transplant recipients.

219 wth and safety parameters in pediatric solid organ transplant recipients.

220 compromised individuals, especially in solid-organ transplant recipients.

221 ost common single cause of death observed in organ transplant recipients.

222 cognized but uncommon complications in solid organ transplant recipients.

223 nues to affect a high proportion of thoracic organ transplant recipients.

224 and the incidence of skin cancer in nonwhite organ transplant recipients.

225 eading cause of cancer mortality among solid organ transplant recipients.

226 MF-59) may lead to greater immunogenicity in organ transplant recipients.

227 e groin and genitalia is imperative in black organ transplant recipients.

228 r for cytomegalovirus (CMV) disease in solid organ transplant recipients.

229 r cause of graft loss and mortality in solid organ transplant recipients.

230 ne the underlying mechanism of recurrence in organ transplant recipients.

231 ce in the prevention of skin cancer in black organ transplant recipients.

232 mentation, which was not seen in other solid-organ transplant recipients.

233 ng nonurologic surgeries, and nonrenal solid-organ transplant recipients.

234 ventions to support self-management in solid organ transplant recipients.

235 9 has the potential to severely impact solid organ transplant recipients.

236 ogy and outcomes of COVID-19 infection among organ transplant recipients.

237 r cytomegalovirus (CMV) prophylaxis in solid-organ transplant recipients.

238 PA) and its correlates and outcomes in solid organ transplant recipients.

239 resistant/recurrent cytomegalovirus in solid-organ transplant recipients.METHODSIn the present study,

240 413 patients (62.7%) evaluated were nonwhite organ transplant recipients; 264 were men, and 149 were

241 V infection, 18 HEV-exposed immunosuppressed organ-transplant recipients (8 with chronic HEV), and 27

242 se of skin cancer after retransplantation in organ-transplant recipients who have already developed p

243 Organ-transplant-recipients exhibit cancerization of the

244 MEK procedures registered in the Netherlands Organ Transplant Registry were identified.

245 Suppression of solid-organ transplant rejection has traditionally focused on

246 perfusion injury; however, it also occurs in organ transplant rejection, major trauma, severe burns,

247 iferative disease (PTLD) arising after solid organ transplant remains contentious.

248 nation and synergy between corneal and solid organ transplant research communities.

249 mics willingness-to-pay threshold to a solid organ transplant setting by coining a new metric: the wi

250 r HLA class I has potential use in the whole organ transplant setting with retained activity at lower

251 Records of solid organ transplant (SOT) and hematopoietic cell transplant

252 describing antibiotic allergies among solid organ transplant (SOT) and hematopoietic cell transplant

253 seases physicians in persons receiving solid organ transplant (SOT) between May 2008 and December 201

254 xercise training in adult and children solid organ transplant (SOT) candidates and recipients and on

255 Solid organ transplant (SOT) candidates and recipients are at

256 In this cross-sectional study of solid organ transplant (SOT) candidates and recipients, we qua

257 d molecular pretransplant screening in solid organ transplant (SOT) donors and recipients in north ce

258 Two groups were identified: the solid organ transplant (SOT) group (n = 15; 12 ITX and 3 modif

259 ll coronavirus disease 2019 (COVID-19) solid organ transplant (SOT) patients are limited.

260 Despite annual immunization, solid organ transplant (SOT) patients remain at increased risk

261 nses to natural influenza infection in solid organ transplant (SOT) patients.

262 Solid organ transplant (SOT) recipients are at elevated risk o

263 ematopoietic cell transplant (HCT) and solid organ transplant (SOT) recipients are at increased risk

264 Solid organ transplant (SOT) recipients are at risk of nocardi

265 rovecii pneumonia (PJP) prophylaxis in solid organ transplant (SOT) recipients at increased risk.

266 evere infections in seronegative adult solid organ transplant (SOT) recipients but can be prevented b

267 Solid organ transplant (SOT) recipients comprise a large propo

268 In fall 2017, 3 solid organ transplant (SOT) recipients from a common donor de

269 immune responses in HIV-infected adult solid organ transplant (SOT) recipients on antiretroviral ther

270 al response (SVR) in a large cohort of solid organ transplant (SOT) recipients with chronic HEV infec

271 itis can cause intractable diarrhea in solid organ transplant (SOT) recipients, for which there are n

272 mong immunosuppressed patients such as solid organ transplant (SOT) recipients, who are at presumed r

273 re in adolescent and young adult (AYA) solid organ transplant (SOT) recipients.

274 ciated with morbidity and mortality in solid organ transplant (SOT) recipients.

275 s an emerging and important problem in solid organ transplant (SOT) recipients.

276 ve the potential to affect outcomes in solid organ transplant (SOT) recipients.

277 portionately more severe disease among solid organ transplant (SOT) recipients.

278 out COVID-19, including its effects on solid organ transplant (SOT) recipients.

279 or cause of morbidity and mortality in solid organ transplant (SOT) recipients.

280 ecting 0.04% to 3.5% of patients after solid organ transplant (SOT).

281 Sepsis is a serious complication of solid organ transplant (SOT).

282 uman immunodeficiency virus (HIV), and solid organ transplant (SOT).

283 unosuppression (120; 82.8%), including solid organ transplant (SOT; 33.8%), autoimmunity (15.9%), and

284 hematologic and solid tumor), HIV, and solid organ transplant (SOT; kidney and other).

285 ients waitlisted for and recipients of solid organ transplants (SOT) are perceived to have a higher r

286 over the years shows that, similar to solid organ transplants (SOT), human VCA can also develop CR.

287 d by invasive biopsy for monitoring of solid organ transplants (SOTs).

288 ng revised CMV guidelines should incorporate organ transplant-specific thresholds of prior drug expos

289 n, which is in sharp contrast to other solid organ transplants, such as kidney, lung, and heart trans

290 ients already on immunosuppression for other organ transplant, there is little additional risk involv

291 ignificant clinical problem across all solid organ transplants, there are limited therapeutics and pa

292 s with cystic fibrosis who never received an organ transplant; this strategy prevented 79% of deaths

293 s with cystic fibrosis who never received an organ transplant; this strategy prevented 79% of deaths

294 e, type and location of skin cancer, type of organ transplanted, time to diagnosis of skin cancer aft

295 During 2009 and 2010, 2 clusters of organ transplant-transmitted Balamuthia mandrillaris, a

296 ls with inflammatory bowel diseases or solid-organ transplants, virome dynamics in allogeneic hematop

297 Patients on organ transplant waiting lists are evaluated for preexis

298 ants and reduced long-term survival of solid organ transplants, we hypothesized that conventional imm

299 The two primary endpoints for each type of organ transplant were date of first registration of a tr

300 The indication and type of organ transplant were recorded in addition to the amyloi